



September 6, 2017

## **Anthera Pharmaceuticals to Present at Rodman & Renshaw's 18th Annual Global Investment Conference**

HAYWARD, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy, announced today that Craig Thompson, President & Chief Executive Officer, will present a corporate update at Rodman & Renshaw's 18<sup>th</sup> Annual Global Investment Conference.

The presentation will be at 10:25 AM ET, September 12<sup>th</sup>, at the Lotte New York Palace Hotel in New York.

The audio portion of the presentation will be accessible through the company's Investors page at [www.anthera.com/investors](http://www.anthera.com/investors) following the presentation.

### **About Anthera Pharmaceuticals, Inc.**

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy. Additional information on Anthera can be found at [www.anthera.com](http://www.anthera.com).

### **Safe Harbor Statement**

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

### **Contact Information**

CONTACT: Investor Relations of Anthera Pharmaceuticals, Inc.

[ir@anthera.com](mailto:ir@anthera.com)

For Media Inquiries:

Srikant Ramaswami

rbb Communications

[srikant.ramaswami@rbcommunications.com](mailto:srikant.ramaswami@rbcommunications.com)

718-710-1350

[www.twitter.com/antherapharma](http://www.twitter.com/antherapharma)

<https://www.facebook.com/antherapharma/>

<https://www.linkedin.com/company/anthera-pharmaceuticals>

 Primary Logo

Source: Anthera Pharmaceuticals, Inc.

News Provided by Acquire Media